Abstract
Dyslipidaemia is common in solid organ transplant recipients and its presence is associated with chronic rejection and accelerated atherosclerosis, leading to an increased prevalence of cardiovascular disease (CVD). CVD is a major cause of morbidity and mortality in transplant recipients. It is therefore of interest and clinical value to introduce agents that effectively and safely reduce the incidence of this outcome. In the present review we consider the potential benefits of statin administration in adults who have undergone solid organ (mainly renal, heart and liver) transplantation, as well as in paediatric transplant patients. We also briefly review the effects of combination therapy with ezetimibe and statins in this population. Overall, statins are efficient and safe drugs for the management of dyslipidaemias in transplant populations, and in most trials they had a beneficial effect on long-term survival rates, CVD events and rejection rates. The transplanted population is different from other patient groups, mostly due to concomitant immunosuppressive therapy. Statins, at an appropriate dosage, should be prescribed to dyslipidaemic transplanted patients but they should be closely monitored for adverse effects.
Keywords: Statins, dyslipidaemia, transplantation, cardiovascular disease, atherosclerosis, rejection
Current Pharmaceutical Design
Title: Statins and Solid Organ Transplantation
Volume: 12 Issue: 36
Author(s): I. F. Gazi, E. N. Liberopoulos, V. G. Athyros, M. Elisaf and D. P. Mikhailidis
Affiliation:
Keywords: Statins, dyslipidaemia, transplantation, cardiovascular disease, atherosclerosis, rejection
Abstract: Dyslipidaemia is common in solid organ transplant recipients and its presence is associated with chronic rejection and accelerated atherosclerosis, leading to an increased prevalence of cardiovascular disease (CVD). CVD is a major cause of morbidity and mortality in transplant recipients. It is therefore of interest and clinical value to introduce agents that effectively and safely reduce the incidence of this outcome. In the present review we consider the potential benefits of statin administration in adults who have undergone solid organ (mainly renal, heart and liver) transplantation, as well as in paediatric transplant patients. We also briefly review the effects of combination therapy with ezetimibe and statins in this population. Overall, statins are efficient and safe drugs for the management of dyslipidaemias in transplant populations, and in most trials they had a beneficial effect on long-term survival rates, CVD events and rejection rates. The transplanted population is different from other patient groups, mostly due to concomitant immunosuppressive therapy. Statins, at an appropriate dosage, should be prescribed to dyslipidaemic transplanted patients but they should be closely monitored for adverse effects.
Export Options
About this article
Cite this article as:
Gazi F. I., Liberopoulos N. E., Athyros G. V., Elisaf M. and Mikhailidis P. D., Statins and Solid Organ Transplantation, Current Pharmaceutical Design 2006; 12 (36) . https://dx.doi.org/10.2174/138161206779026308
DOI https://dx.doi.org/10.2174/138161206779026308 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protective Effects of Terpenes on the Cardiovascular System: Current Advances and Future Perspectives
Current Medicinal Chemistry Fast Food Versus Slow Food and Hypertension Control
Current Hypertension Reviews Towards a Better Understanding of Cardiac and Vascular Disease in Patients with Chronic Kidney Disease
Current Cardiology Reviews Left Ventricular Hypertrophy and Angiotensin II Receptor Blocking Agents
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Ischemic Strokes in Congenital Bleeding Disorders: Comparison with Myocardial Infarction and other Acute Coronary Syndromes
Cardiovascular & Hematological Disorders-Drug Targets Recent Developments in the Field of Quinazoline Chemistry
Current Organic Chemistry The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry Cystathionine Beta Synthase as a Risk Factor for Alzheimer Disease
Current Alzheimer Research Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A
Current Medicinal Chemistry The Development of Antibody-based Immunotherapy for Methamphetamine Abuse: Immunization, and Virus-Mediated Gene Transfer Approaches
Current Gene Therapy Biological Consequences of Dysfunctional HDL
Current Medicinal Chemistry Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Encapsulation of Plant-derived Bioactive Ingredients through Electrospraying for Nutraceuticals and Functional Foods Applications
Current Medicinal Chemistry QT Alterations in Psychopharmacology: Proven Candidates and Suspects
Current Drug Safety Epidemiology of Gout: Perspectives from the Past
Current Rheumatology Reviews What Restricts the Clinical Use of Nicotinic Acid?
Current Vascular Pharmacology Clinical Relevance of Postprandial Lipaemia
Current Medicinal Chemistry Improvement in Hypertension Management with Pharmacological and Non- Pharmacological Approaches: Current Perspectives
Current Pharmaceutical Design Randomized Clinical Stroke Trials in 2006
Current Vascular Pharmacology COVID-19 Severity: Lung-Heart Interplay
Current Cardiology Reviews